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Dopamine dysregulation syndrome is a complication of the dopaminergic treatment in Parkinson’s disease that may be very
disabling due to the negative impact that compulsive medication use may have on patients’ social, psychological, and physical
functioning. The relationship between subthalamic nucleus deep brain stimulation and dopamine dysregulation syndrome in
patients with Parkinson’s disease remains unclear. Deep brain stimulation may improve, worsen, or have no eﬀect on preoperative
dopamine dysregulation syndrome. Moreover, dopamine dysregulation syndrome may appear for the ﬁrst time after deep
brain stimulation of the subthalamic nucleus. The outcome of postoperative dopamine dysregulation syndrome is poor despite
stimulation and medication adjustments. Here we review the phenomenology and neurobiology of this disorder, discuss possible
mechanisms that may underlie the diverse outcomes of dopamine dysregulation syndrome after subthalamic nucleus deep brain
stimulation, and propose management strategies.
1.DopamineDysregulation
Syndrome: Phenomenology, Epidemiology,
andRiskFactors
Dopamine dysregulation syndrome (DDS), originally de-
scribed as “hedonistic homeostatic dysregulation” by Gio-
vannoni et al. [1], is a disturbance that may complicate long-
term dopamine replacement therapy (DRT) of Parkinson’s
disease(PD).PatientswithDDSdevelopanaddictivepattern
of DRT use, self-administering doses of dopaminergic drugs
in excess of those required to control their motor symptoms.
Patients demand drug escalation and a compulsive DRT
seeking and intake is developed, taking larger levodopa doses
thanprescribed. Theyjustifytheoveruseofantiparkinsonian
drugs, despite being very dyskinetic, to avoid the nonmotor
aspectsrelatedto“oﬀ”statesuchasanxiety,depressedmood,
or fear sensation. Attempts made by physicians to reduce
DRT doses are received with resistance and commonly are
unsuccessful [2].
DDS has been related to levodopa and potent short-
acting dopamine agonists as subcutaneous apomorphine,
butitalsocanoccurwithotherdopamineagonists.Thecom-
pulsive use of DRT may lead to negative social behaviours
such as hoarding medication.
DDSmayencompassotherpsychomotorpathologiesdue
to antiparkinsonian therapy as punding—complex mean-
ingless stereotyped and repetitive motor behaviours—and
impulse control disorders, such as pathological gambling,
hypersexuality, compulsive shopping, and binge eating [2].
DDS is probably underdiagnosed because patients may
not complain of their behaviour and physicians may forget
to ask about that. There are no large epidemiological studies
about the prevalence of DDS in the general PD population.
The prevalence of DDS in patients attending Parkinson’s
disease centers is 3-4% [1, 3].
The DDS diagnostic criteria proposed by Giovannoni et
al. [1] in his seminal paper were (a) PD with documented
levodopa responsiveness; (b) need for increasing doses of
DRT in excess of those normally required to relieve parkin-
sonian symptoms and signs; (c) pattern of pathological use:
expressedneedforincreasedDRTinthepresenceofexcessive
and signiﬁcant dyskinesias despite being “on”, drug hoarding2 Neurology Research International
or drug seeking behaviour, unwillingness to reduce DRT,
and absence of painful dystonias; (d) impairment in social
or occupational functioning: ﬁghts, violent behaviour, loss
of friends, absence from work, loss of job, legal diﬃculties,
arguments or diﬃculties with family; (e) development of
hypomaniac, maniac, or cyclothymic aﬀective syndrome in
relation to DRT; (f) development of a withdrawal state char-
acterized by dysphoria, depression, irritability, and anxiety
on reducing the level of DRT; (g) duration of disturbance of
at least 6 months.
Pezzella et al. used the following selection criteria for
DDS [3]: (a) PD with documented levodopa responsiveness;
(b) need to increase doses of DRT beyond those normally
required to relieve parkinsonian symptoms and signs; (c)
pattern of pathological use of DRT (chronic medication
abuse, excluding occasional dosage increase while experienc-
ing a sudden oﬀ or preparing for a social event) and current
mood disorders (depression, anxiety, hypomaniac state,
euphoria), behavioural disorders (pathological gambling,
obsessional shopping, hypersexuality, aggression, social iso-
lation), or alteration of the perception of the on state (walk-
abouts, stereotypies).
Some factors may contribute or predispose to develop
DDS in PD patients.
Impulsivity and sensation and novelty-seeking person-
ality traits have been found in patients with PD and DDS
[4–6]. It has been also noticed that young-onset PD patients
a r em o r ev u l n e r a b l et od e v e l o pt h i ss y n d r o m e[ 5]. Other
reported risk factors are male gender, previous history of
substance abuse (alcohol, drugs, etc.), higher dopaminergic
drug intake, and presence of depressive symptoms [4–7].
Recently, engagement in a creative or artistic profession has
been described as an additional risk factor for developing
DDS [8].
Genetic factors may also be relevant [6]. It has been
suggested that parkin gene mutations (PARK2) may be a
risk factor for developing DDS [9, 10]. O’Sullivan et al. [4]
proposed that “D2-like” receptor family genes could play
a role in the pathogenesis of DDS. In PET studies with
[11C]-raclopride, Parkin-positive medicated patients have
been reported to show a signiﬁcant decrease of D2 striatal
receptors in comparison with idiopathic PD medicated
patients and with age-matched healthy controls [10].
2. Neurobiology of DDS
Many PD patients with DDS fulﬁl DSM-IV criteria for
substance dependence because of the negative eﬀect that the
pathological use of medication has on their social, psycho-
logical, and physical functioning [11].
The negative reinforcement model is one of the pro-
posed theories to explain addiction [2]. Based on this
model, patients with DDS may use dopaminergic drugs
to avoid dysphoric oﬀ states. However, the model that
may better explain the pathophysiology of DDS is the
incentive-sensitizationtheory[4,7].Thistheoryofaddiction
postulates that compulsive drug use modiﬁes dopaminergic
neurotransmission in the nucleus accumbens and related
reward circuitry involving the mesocorticolimbic dopamine
system[11].Thisneuroadaptationontheaccumbens-related
circuitry makes the system sensitized to the psychomotor
eﬀects of drugs [7]. Thus, the potential addictive pattern
of antiparkinsonian drugs may be related to their eﬀect
on the reward system. Some experimental data on the
activation of accumbens-related reward-seeking pathways
by DRT suggested that antiparkinsonian drugs share some
properties with addictive psychostimulants as amphetamine
[7].
There is evidence of sensitization of the ventral striatum
reward system by PET imaging with [11C]-raclopride in
PD patients with DDS who had enhanced levodopa-induced
ventral striatal dopamine release compared with levodopa-
treated patients with no compulsive drug use [11]. Thus, PD
patients with more pronounced mesolimbic dopaminergic
denervation, involving the ventral striatum (nucleus accum-
bens), may be prone to develop compulsive behaviours after
dopaminergic treatment [11, 12].
3.DopamineDysregulationSyndromeand
SubthalamicNucleusDeepBrainStimulation
Deep brain stimulation of the subthalamic nucleus (STN-
DBS) is an established therapy for advanced PD patients
with motor complications [13]. Bilateral continuous high-
frequency stimulation of the STN improves motor disability
by 33–67%, motor ﬂuctuations by 73–83%, and levodopa-
induced dyskinesias by 55–88% and permits a 40–80%
reduction in the doses of antiparkinsonian medication,
compared with the preoperative state [14]. However, adverse
neurocognitive, mood, and behavioral changes may appear
after STN-DBS [15].
Despite the motor improvement of patients who under-
went STN-DBS, its eﬀect on nonmotor symptoms of Parkin-
son’sdisease,especiallyneurobehavioraldisordersasimpulse
control disorders, punding, and DDS has not been widely
studied.
The relationship between STN-DBS and DDS in patients
with Parkinson’s disease remains unclear. While some
authors described a complete resolution of the behaviour
disorder after STN-DBS [16–19], others found no improve-
ment or even worsening of DDS postoperatively [18].
Furthermore, de novo DDS may appear as a complication
of STN-DBS [14, 19–21].
3.1. Dopamine Dysregulation Syndrome Improved or Resolved
after DBS. To our knowledge, there are 9 PD patients with
DDS reported in the literature who improved or resolved
after STN-DBS [16–19]. Witjas et al. described two patients
with preoperative DDS that resolved immediately after
surgerywithoutrecurrenceofthecompulsivemedicationuse
in successive years [16]. Knobel et al. described a PD patient
suﬀering from severe DDS necessitating in-ward psychiatric
management, who, following STN-DBS and medication
reduction, had a rapid and dramatic resolution of DDS
and associated psychiatric symptoms [17]. Bandini et al.
reported one patient who had also a great improvement ofNeurology Research International 3
DDS within the ﬁrst month after surgery [18]. Lim and
colleagues described three resolved DDS cases after STN-
DBS and other two patients that improved their behaviour
after the procedure [19].
Postoperative DDS improvement may be related to the
reduction of dopaminergic agents allowed by surgery [16,
19, 22]. Decreasing the pulsatile administration of levodopa
may decrease the experience of negative emotional states and
reducetheabnormalsensitizationofmotivationalsymptoms
associated with the mesolimbic system [7]. However this
argument cannot be applied in all cases [19].
3.2. DDS Remained Unchanged or Worsened after DBS. Sub-
thalamic nucleus deep brain stimulation may not inﬂuence
DDS evolution or even can worsen it. 71% of patients
with preoperative DDS reported by Lim et al. (12 patients)
remained unimproved or worsened after surgery [19].
3.3. De Novo DDS after DBS. Interestingly, dopamine dys-
regulation syndrome can also appear for the ﬁrst time
after deep brain stimulation of the subthalamic nucleus. We
reviewedtheliteraturesearchingforreportsofPDpatientsin
whom DDS appeared within 12 months of STN-DBS. To our
knowledge, at least, 7 cases have been reported [14, 19–21].
The ﬁrst patient with postoperative DDS was reported by
Houeto et al. in 2002 [14], a 61-year-old man with personal
history of alcohol misuse and bipolar disorder before the
onset of the disease. The motor outcome after surgery was
good (UPDRS III improved by 86%), although daily lev-
odopa dose was reduced only by 12%. Diverse medications,
stimulation adjustments, and psychotherapy did not resolve
DDS. Three years later, the same group published a ﬁve-year
followup of 37 PD patients treated with STN-DBS in their
center [20]. They reported 3 patients addicted to levodopa
treatment as permanent adverse eﬀect related to medical
treatment, bilateral STN-DBS, or progression of the disease
[20]. We assume all these patients presented the DDS for
the ﬁrst time after surgery. Probably the case described by
Houeto et al. [14] is one of the three cases reported.
Lim and colleagues reported in 2009 two patients with
DDS which apparently appeared for the ﬁrst time after
bilateral STN-DBS [19]. However, one of the reported cases
is not considered in this paper since DDS occurred 8 years
after surgery in the context of a battery failure.
We have recently reported three PD patients who devel-
oped DDS within a year after surgery [21]. The ﬁrst case
was a 47-year-old woman who underwent STN-DBS for a
10-year history of PD complicated with motor ﬂuctuations
and disabling dyskinesias. Neuropsychological exam prior
to surgery was unremarkable. She had been treated with
diﬀerent antiparkinsonian drugs, including subcutaneous
infusion of apomorphine. After DBS, oﬀ periods were
signiﬁcantly reduced, dyskinesias decreased, and medical
treatment was reduced by 50% (apomorphine infusion
was stopped). Six months after surgery, despite her motor
improvement, her husband reported a compulsive intake
of levodopa. The patient justiﬁed the overuse because “she
felt herself as empty of energy.” In addition, she exhibited
binge eating. Therapeutic approaches included pramipexole
withdrawal, DBS adjustments, and addition of quetiapine
and lorazepam, but ﬁve years after surgery she continued to
overuse levodopa. The second case was a 59-year-old man
with a 7-year history of PD complicated with motor ﬂuctu-
ations and mild depressive symptoms. Before surgery he was
treated with high doses of levodopa plus multiple boluses
of subcutaneous apomorphine. Despite the clinical motor
improvement after STN-DBS, four months after surgery,
the patient kept injecting himself apomorphine to avoid
anxiety, depressive mood, and fear sensation. Addition of
quetiapine, citalopram, and DBS parameter adjustments did
not resolve the behaviour, and DDS persisted four years after
surgery. The third patient was a 45-year-old man with PD
since the age of 30, without previous psychiatric history who
underwent STN-DBS surgery for severe motor ﬂuctuations.
A month after STN-DBS procedure, he started drinking high
quantity of caﬀeine-rich beverages (coke) and developed
hypersexuality. Two months later he admitted taking double
dose of pramipexole than prescribed because he felt he
“needed” it. Citalopram and quetiapine were prescribed and
pramipexole tapered. Hypersexuality and compulsive coke
drinking disappeared, but the patient became apathetic and
began to overuse levodopa. In these cases DBS disconnection
was tried, but switching oﬀ DBS led to rapid deterioration of
their motor function in a matter of hours, a situation which
was not tolerated by the patients.
A deﬁnite causal relationship with STN-DBS cannot be
made since the outcome of DDS after discontinuing DBS
could not be assessed—our patients did not tolerate it for
the rapid worsening of their motor performance. Besides,
DDS could have appeared in the evolution of the patients’
disease independently of the surgical treatment. However,
thetemporalrelationshipbetweenSTN-DBSsurgeryandthe
onset of DDS suggests that STN-DBS might have played a
role in the appearance of DDS.
One possible explanation for the appearance or worsen-
ing of DDS after STN-DBS could be misplacement of the
electrodes in the medial zone of the STN, which corresponds
to its limbic territory [23] and is related to motivational
and emotional aspects of behavior [23, 24]. This explana-
tion, however, seems unlikely since in all reported patients
the motor outcome of the surgery was as expected after
stimulation of the dorsolateral sensorimotor part of the
STN [14]. However, due to the small size of the STN,
stimulation with electrode contacts located mainly within
the sensorimotor territory can result in the spread of current
to associative and limbic areas as well as to surrounding
structures [25]. Computational modelling to measure the
volume of activated tissue during DBS is currently being
investigated [25, 26].
Several neuroimaging studies have found that STN-DBS
induced metabolic modiﬁcations in cortical and subcortical
structures related to limbic and associative circuits [26–28].
Thus, the spread of stimulation to associative and limbic
areas of the STN may underlie the appearance of DDS after
DBS surgery. Impulse control disorders such as pathological
gambling have also been reported after DBS [29, 30]a sw e l l
as impulsive behaviour during high-conﬂict decisions [31]4 Neurology Research International
and apathy [32]. Indeed, besides DDS, most of the patients
developed other behavioural addictions such as pathological
gambling and abnormal sexual behaviour [14], binge eating
[21], punding, and compulsive shopping [19].
On the other hand, the psychostimulant eﬀect of STN-
DBS [33, 34] seems an unlikely explanation for de novo DDS
after surgery.
The seemingly paradoxical occurrenceofeither improve-
ment or worsening of DDS after STN-DBS or, furthermore,
the de novo appearance of this addictive behaviour may be
related to individual diﬀerences in the extent of mesolimbic
dopaminergic denervation [22, 35]. PET studies comparing
PD patients with postoperative apathy after dopamine
agonist withdrawal with nonapathetic patients have revealed
areas of increased [11C]-raclopride binding potential values
in the orbitofrontal, dorsolateral, prefrontal, and posterior
cingulate cortices as well as other subcortical structures
includingtheamygdalaandtheventralstriatumbilaterallyin
the apathetic group, thus suggesting the existence of diﬀerent
nonmotor phenotypes [22].
Reward-seeking behavior is mediated by the amygdala
and nucleus accumbens, both of which receive dopaminergic
projections from the ventral tegmental area [36]. Thus, PD
patients with more pronounced mesolimbic dopaminergic
denervation involving the ventral striatum (nucleus accum-
bens) may be prone to developing compulsive behaviours
after dopaminergic treatment [5, 12].
This might be the case of de novo DDS patients, in
whom the combined eﬀect of dopaminergic replacement
therapy (albeit reduced after surgery) and DBS on the limbic
territory of the STN could have led to hyperstimulation of
the mesolimbic system, thus precipitating the onset of DDS.
4. Management of Dopamine Dysregulation
Syndrome in the Context of STN-DBS
The clinical management of DDS is challenging, particularly
when appears after STN-DBS. Despite a good postoperative
motor outcome, most patients overused dopaminergic drugs
not because they felt pleasurable eﬀects but to avoid anxiety,
dysphoria, and other nonmotor symptoms [2, 21, 37].
Preoperative recognition of DDS and other impulse
control disorders is correlated with a better outcome of these
behaviours after DBS, whereas lack of recognition, poor
motor beneﬁt, and higher dopaminergic medication doses
after surgery were associated with persistence or even new
cases of DDS [19].
Changes in stimulation parameters, attempts to reduce
the dose of dopaminergic drugs, and the addition of antipsy-
chotics and/or antidepressants may not be helpful. The
outcome of DDS after STN-DBS was poor in the majority
of reported cases [14, 19–21].
The issue of how to manage antiparkinsonian drugs
after STN-DBS remains unsettled. A large and rapid reduc-
tion in dopamine replacement therapy with withdrawal of
dopaminergicagonistsmayinduceapathyandseveredepres-
sion in many patients [22], whereas a more conservative
approach may precipitate DDS in some cases.
Identifying vulnerable patients to develop DDS seems
of paramount relevance. Young-onset PD, male gender,
previous history of substance abuse, impulsive sensation
seeking personality, presence of depressive symptoms, and
artisticprofessionshavebeenconsideredriskfactorsforDDS
[4–8] as well as treatment with high doses of dopaminergic
medication and rapid acting dopaminergic drugs [4–7].
Perhaps detailed neuropsychological evaluations using scales
such as QUIP (Questionnaire for Impulsive and Compulsive
Disorders in Parkinson’s disease) [38]o rP E Ts t u d i e st od e t e c t
cases of severe denervation of the mesolimbic dopaminergic
system [22] may be useful tools to identify potential DDS
patients.
The adequate location of electrodes is another crucial
factor. Contacts close to the ventromedial part of the
STN should be avoided. Perhaps the use of computational
modelling [25, 26], when it becomes available, could help
elucidatethebestsetofstimulationparametersforindividual
patients.
Nevertheless, it seems advisable to avoid a hyper-
dopaminergic state during the postoperative period, since
high doses of dopaminergic medication added to STN-DBS
therapy may predispose to developing DDS in vulnerable
patients.
Further research should be undertaken in order to iden-
tify patients who are vulnerable to DDS and to deﬁne the
most appropriate postoperative management.
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